Amgen's anti-inflammatory Otezla makes its foray into COVID-19

At the J.P. Morgan Healthcare Conference in January—back when few could predict the looming destruction of COVID-19—Amgen CEO Bob Bradway vowed the company would find new ways to make its $13.4 billion acquisition of Celgene’s psoriasis drug Otezla worth the investment. Now, COVID-19 is presenting one such opportunity.